BBOT — Bridgebio Oncology Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.05bn
- $1.05bn
- 37
- 24
- 66
- 37
Annual balance sheet for Bridgebio Oncology Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | — | — | — | 1.7 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0.144 | 0.145 | 0.333 | 1.95 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 0.144 | 0.145 | 0.333 | 194 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 0.163 | 0.166 | 0.396 | 0.188 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0.163 | 0.166 | 0.396 | 5.71 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | -0.018 | -0.022 | -0.064 | 189 |
| Total Liabilities & Shareholders' Equity | 0.144 | 0.145 | 0.333 | 194 |
| Total Common Shares Outstanding |